Amedisys (NASDAQ:AMED) Sees Unusually-High Trading Volume

Amedisys, Inc. (NASDAQ:AMED) saw unusually-strong trading volume on Monday . Approximately 297,339 shares traded hands during trading, a decline of 1% from the previous session’s volume of 301,440 shares.The stock last traded at $97.20 and had previously closed at $97.25.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Raymond James reiterated a “market perform” rating on shares of Amedisys in a research note on Tuesday, March 26th. William Blair downgraded shares of Amedisys from an “outperform” rating to a “market perform” rating in a research note on Monday, July 1st. Royal Bank of Canada raised their price target on Amedisys from $97.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 25th. StockNews.com raised Amedisys from a “hold” rating to a “buy” rating in a report on Saturday, May 4th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $101.00 price objective on shares of Amedisys in a report on Thursday, April 25th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Amedisys currently has a consensus rating of “Hold” and a consensus target price of $100.67.

Amedisys Price Performance

The company has a debt-to-equity ratio of 0.31, a current ratio of 1.09 and a quick ratio of 1.09. The firm has a market cap of $3.20 billion, a price-to-earnings ratio of -152.39, a PEG ratio of 2.38 and a beta of 0.79. The stock has a 50-day moving average price of $93.87 and a 200 day moving average price of $93.52.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, April 24th. The health services provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Amedisys had a positive return on equity of 12.85% and a negative net margin of 0.91%. The firm had revenue of $571.41 million for the quarter, compared to the consensus estimate of $565.38 million. During the same quarter last year, the business posted $1.00 EPS. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. As a group, equities research analysts forecast that Amedisys, Inc. will post 4.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Amedisys

Several institutional investors and hedge funds have recently added to or reduced their stakes in AMED. Retirement Systems of Alabama lifted its holdings in shares of Amedisys by 0.3% in the 4th quarter. Retirement Systems of Alabama now owns 40,871 shares of the health services provider’s stock valued at $3,885,000 after buying an additional 125 shares during the period. Treasurer of the State of North Carolina raised its position in Amedisys by 1.0% in the fourth quarter. Treasurer of the State of North Carolina now owns 14,204 shares of the health services provider’s stock worth $1,350,000 after acquiring an additional 140 shares in the last quarter. Louisiana State Employees Retirement System lifted its holdings in Amedisys by 2.2% in the first quarter. Louisiana State Employees Retirement System now owns 9,400 shares of the health services provider’s stock valued at $866,000 after acquiring an additional 200 shares during the period. Bridge City Capital LLC boosted its position in shares of Amedisys by 0.8% during the 1st quarter. Bridge City Capital LLC now owns 29,861 shares of the health services provider’s stock worth $2,752,000 after purchasing an additional 231 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Amedisys by 0.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,199 shares of the health services provider’s stock worth $2,876,000 after purchasing an additional 255 shares during the period. Institutional investors and hedge funds own 94.36% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.